Which has stronger valuation & earnings, MIRM or NBTX?

Mirum Pharmaceuticals has higher revenue and earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mirum Pharmaceuticals $521.31M 10.71 -$23.36M -$14.55 N/A Nanobiotix $36.87M 32.51 -$27.11M N/A N/A

Does the media favor MIRM or NBTX?

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Nanobiotix. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 2 mentions for Nanobiotix. Mirum Pharmaceuticals' average media sentiment score of 0.99 beat Nanobiotix's score of 0.89 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ERAS or NBTX?

Nanobiotix has higher revenue and earnings than Erasca. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.95 N/A Nanobiotix $36.87M 32.51 -$27.11M N/A N/A

Is ERAS or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -38.43% -32.05% Nanobiotix N/A N/A N/A

Does the media favor ERAS or NBTX?

In the previous week, Erasca had 3 more articles in the media than Nanobiotix. MarketBeat recorded 5 mentions for Erasca and 2 mentions for Nanobiotix. Erasca's average media sentiment score of 0.91 beat Nanobiotix's score of 0.89 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, DNTH or NBTX?

Nanobiotix has higher revenue and earnings than Dianthus Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dianthus Therapeutics $2.04M 2,212.68 -$162.34M -$4.15 N/A Nanobiotix $36.87M 32.51 -$27.11M N/A N/A

Does the media favor DNTH or NBTX?

In the previous week, Dianthus Therapeutics had 1 more articles in the media than Nanobiotix. MarketBeat recorded 3 mentions for Dianthus Therapeutics and 2 mentions for Nanobiotix. Dianthus Therapeutics' average media sentiment score of 1.06 beat Nanobiotix's score of 0.89 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, EWTX or NBTX?

Nanobiotix has higher revenue and earnings than Edgewise Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A Nanobiotix $36.87M 32.51 -$27.11M N/A N/A

Is EWTX or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% Nanobiotix N/A N/A N/A

Does the media prefer EWTX or NBTX?

In the previous week, Edgewise Therapeutics had 2 more articles in the media than Nanobiotix. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 2 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.89 beat Edgewise Therapeutics' score of 0.16 indicating that Nanobiotix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Nanobiotix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, RLAY or NBTX?

Nanobiotix has higher revenue and earnings than Relay Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relay Therapeutics $15.35M 255.26 -$276.48M -$1.57 N/A Nanobiotix $36.87M 32.51 -$27.11M N/A N/A

Is RLAY or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -42.27% -38.67% Nanobiotix N/A N/A N/A

Does the media prefer RLAY or NBTX?

In the previous week, Relay Therapeutics had 9 more articles in the media than Nanobiotix. MarketBeat recorded 11 mentions for Relay Therapeutics and 2 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.89 beat Relay Therapeutics' score of 0.57 indicating that Nanobiotix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nanobiotix (NBTX) Competitors

$23.68 +0.78 (+3.41%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$23.72 +0.04 (+0.15%)

As of 10/9/2026 07:30 PM Eastern

Compare

NBTX vs. MIRM, ERAS, DNTH, EWTX, and RLAY

Should you buy Nanobiotix stock or one of its competitors? Nanobiotix's main competitors and comparable companies include Mirum Pharmaceuticals (MIRM), Erasca (ERAS), Dianthus Therapeutics (DNTH), Edgewise Therapeutics (EWTX), and Relay Therapeutics (RLAY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nanobiotix compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Mirum Pharmaceuticals currently has a consensus target price of $143.81, suggesting a potential upside of 67.20%. Nanobiotix has a consensus target price of $46.67, suggesting a potential upside of 97.07%. Given Nanobiotix's higher possible upside, analysts clearly believe Nanobiotix is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Nanobiotix. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 2 mentions for Nanobiotix. Mirum Pharmaceuticals' average media sentiment score of 0.99 beat Nanobiotix's score of 0.89 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has higher revenue and earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	10.71	-$23.36M	-$14.55	N/A
Nanobiotix	$36.87M	32.51	-$27.11M	N/A	N/A

Nanobiotix has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Nanobiotix's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Nanobiotix	N/A	N/A	N/A

38.8% of Nanobiotix shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Mirum Pharmaceuticals has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

Summary

Mirum Pharmaceuticals beats Nanobiotix on 8 of the 15 factors compared between the two stocks.

How does Nanobiotix compare to Erasca?

Erasca (NASDAQ:ERAS) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

In the previous week, Erasca had 3 more articles in the media than Nanobiotix. MarketBeat recorded 5 mentions for Erasca and 2 mentions for Nanobiotix. Erasca's average media sentiment score of 0.91 beat Nanobiotix's score of 0.89 indicating that Erasca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of Erasca shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 14.2% of Erasca shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nanobiotix's return on equity of 0.00% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-38.43%	-32.05%
Nanobiotix	N/A	N/A	N/A

Erasca has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Erasca presently has a consensus target price of $22.09, suggesting a potential upside of 37.81%. Nanobiotix has a consensus target price of $46.67, suggesting a potential upside of 97.07%. Given Nanobiotix's higher probable upside, analysts clearly believe Nanobiotix is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nanobiotix has higher revenue and earnings than Erasca.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A
Nanobiotix	$36.87M	32.51	-$27.11M	N/A	N/A

Summary

Erasca and Nanobiotix tied by winning 6 of the 12 factors compared between the two stocks.

How does Nanobiotix compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Dianthus Therapeutics presently has a consensus target price of $129.83, indicating a potential upside of 57.62%. Nanobiotix has a consensus target price of $46.67, indicating a potential upside of 97.07%. Given Nanobiotix's higher probable upside, analysts plainly believe Nanobiotix is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Dianthus Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Dianthus Therapeutics had 1 more articles in the media than Nanobiotix. MarketBeat recorded 3 mentions for Dianthus Therapeutics and 2 mentions for Nanobiotix. Dianthus Therapeutics' average media sentiment score of 1.06 beat Nanobiotix's score of 0.89 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nanobiotix has higher revenue and earnings than Dianthus Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,212.68	-$162.34M	-$4.15	N/A
Nanobiotix	$36.87M	32.51	-$27.11M	N/A	N/A

Nanobiotix has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -10,096.95%. Nanobiotix's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
Nanobiotix	N/A	N/A	N/A

Summary

Dianthus Therapeutics beats Nanobiotix on 8 of the 15 factors compared between the two stocks.

How does Nanobiotix compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Nanobiotix's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Nanobiotix	N/A	N/A	N/A

Edgewise Therapeutics currently has a consensus target price of $51.33, suggesting a potential upside of 31.42%. Nanobiotix has a consensus target price of $46.67, suggesting a potential upside of 97.07%. Given Nanobiotix's higher possible upside, analysts plainly believe Nanobiotix is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Edgewise Therapeutics has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

In the previous week, Edgewise Therapeutics had 2 more articles in the media than Nanobiotix. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 2 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.89 beat Edgewise Therapeutics' score of 0.16 indicating that Nanobiotix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nanobiotix has higher revenue and earnings than Edgewise Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Nanobiotix	$36.87M	32.51	-$27.11M	N/A	N/A

38.8% of Nanobiotix shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Nanobiotix beats Edgewise Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Nanobiotix compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Relay Therapeutics had 9 more articles in the media than Nanobiotix. MarketBeat recorded 11 mentions for Relay Therapeutics and 2 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.89 beat Relay Therapeutics' score of 0.57 indicating that Nanobiotix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics has a beta of 1.72, meaning that its share price is 72% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Relay Therapeutics currently has a consensus target price of $25.92, suggesting a potential upside of 44.95%. Nanobiotix has a consensus target price of $46.67, suggesting a potential upside of 97.07%. Given Nanobiotix's higher possible upside, analysts clearly believe Nanobiotix is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nanobiotix's return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Nanobiotix	N/A	N/A	N/A

Nanobiotix has higher revenue and earnings than Relay Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	255.26	-$276.48M	-$1.57	N/A
Nanobiotix	$36.87M	32.51	-$27.11M	N/A	N/A

Summary

Relay Therapeutics beats Nanobiotix on 8 of the 14 factors compared between the two stocks.

Get Nanobiotix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBTX vs. The Competition

Export

Metric	Nanobiotix	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.20B	$3.93B	$7.25B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	N/A	13.55	275.01	26.14
Price / Sales	32.51	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	-12.02	17.17	11.22	6.33
Net Income	-$27.11M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-8.04%	-1.34%	-0.89%	-1.40%
1 Month Performance	-36.02%	-8.04%	-4.02%	-3.35%
1 Year Performance	0.34%	14.18%	7.13%	1.49%

Nanobiotix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBTX Nanobiotix	3.3311 of 5 stars	$23.68 +3.4%	$46.67 +97.1%	+0.3%	$1.20B	$36.87M	N/A	97	Gap Up
MIRM Mirum Pharmaceuticals	3.0192 of 5 stars	$78.91 -3.1%	$142.56 +80.7%	+18.3%	$5.06B	$618.07M	N/A	433	Analyst Forecast
ERAS Erasca	2.5305 of 5 stars	$14.16 -3.8%	$22.09 +56.0%	+563.8%	$4.98B	N/A	N/A	103
DNTH Dianthus Therapeutics	2.7427 of 5 stars	$84.06 -4.5%	$129.83 +54.4%	+139.0%	$4.62B	$1.90M	N/A	92	News Coverage Positive News
EWTX Edgewise Therapeutics	2.5365 of 5 stars	$39.81 -1.2%	$51.33 +28.9%	+158.5%	$4.32B	N/A	N/A	127	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBTX) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanobiotix (NBTX) Competitors

NBTX vs. MIRM, ERAS, DNTH, EWTX, and RLAY

How does Nanobiotix compare to Mirum Pharmaceuticals?

Summary

How does Nanobiotix compare to Erasca?

Summary

How does Nanobiotix compare to Dianthus Therapeutics?

Summary

How does Nanobiotix compare to Edgewise Therapeutics?

Summary

How does Nanobiotix compare to Relay Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanobiotix (NBTX) Competitors

NBTX vs. MIRM, ERAS, DNTH, EWTX, and RLAY

How does Nanobiotix compare to Mirum Pharmaceuticals?

Do analysts rate MIRM or NBTX?

Does the media favor MIRM or NBTX?

Which has stronger valuation & earnings, MIRM or NBTX?

Is MIRM or NBTX more profitable?

Do insiders and institutionals hold more shares of MIRM or NBTX?

Which has more volatility & risk, MIRM or NBTX?

Summary

How does Nanobiotix compare to Erasca?

Does the media favor ERAS or NBTX?

Do institutionals and insiders hold more shares of ERAS or NBTX?

Is ERAS or NBTX more profitable?

Which has more risk & volatility, ERAS or NBTX?

Do analysts recommend ERAS or NBTX?

Which has higher valuation and earnings, ERAS or NBTX?

Summary

How does Nanobiotix compare to Dianthus Therapeutics?

Do analysts prefer DNTH or NBTX?

Which has more risk & volatility, DNTH or NBTX?

Do insiders & institutionals believe in DNTH or NBTX?

Does the media favor DNTH or NBTX?

Which has preferable earnings & valuation, DNTH or NBTX?

Is DNTH or NBTX more profitable?

Summary

How does Nanobiotix compare to Edgewise Therapeutics?

Is EWTX or NBTX more profitable?

Do analysts rate EWTX or NBTX?

Which has more volatility and risk, EWTX or NBTX?

Does the media prefer EWTX or NBTX?

Which has stronger earnings and valuation, EWTX or NBTX?

Do institutionals & insiders believe in EWTX or NBTX?

Summary

How does Nanobiotix compare to Relay Therapeutics?

Do institutionals and insiders have more ownership in RLAY or NBTX?

Does the media prefer RLAY or NBTX?

Which has more volatility & risk, RLAY or NBTX?

Do analysts rate RLAY or NBTX?

Is RLAY or NBTX more profitable?

Which has better earnings and valuation, RLAY or NBTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools